Vaccination of Patients With Oncology Diseases Against Measles and Mumps

Харит, С. М.; Черняева, Т. В.; Черняева, Е. В.; Brusov, N. K.

doi:10.15789/2220-7619-2011-1-85-91

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the comparison group, which included patients who received booster vaccine but did not receive medication support, the proportion of individuals with undetectable anti-measles antibody titers was 26.9% [ 43 ]. Other authors also reported data suggesting that immune-active agents of various types might improve the production of specific anti-measles antibodies [ 44 , 45 , 46 , 47 ].…”

Section: Discussionmentioning

confidence: 99%

Characteristics of Anti-Measles Immunity in Lung Transplant Candidates

Polishchuk,

Kostinov,

Ryzhov

et al. 2023

Viruses

View full text Add to dashboard Cite

Measles has not yet been eradicated; therefore, its outbreaks are still reported throughout the world. Like any infection, measles is dangerous for immunocompromised patients. Levels of anti-measles IgG antibodies were measured in 157 patients aged 17 to 72, who were placed on the lung transplant waiting list. Measurements were undertaken by enzyme-linked immunosorbent assay (ELISA) using the VectoMeasles-IgG kit (Russia). The proportion of patients seronegative for measles was 19% (30/157). Correlation was detected between patients’ age and their levels of anti-measles antibodies, with higher proportions of patients having undetectable titers (25.5–28.9%) or low antibody levels (38.3–44.4%) in the young age groups (17–29 and 30–39 years old). There were no differences between male and female patients in levels of anti-measles antibodies or in the proportion of seronegative individuals. Analyses of antibody levels with regard to type of disease revealed the highest rate of seronegative results in cystic fibrosis patients (34.4%, 11/32). Overall, 19% of lung transplant candidates, mostly young people and cystic fibrosis patients, did not have protective immunity against measles.

show abstract

Section: Discussionmentioning

confidence: 99%

Characteristics of Anti-Measles Immunity in Lung Transplant Candidates

Polishchuk,

Kostinov,

Ryzhov

et al. 2023

Viruses

View full text Add to dashboard Cite

show abstract

Vaccination against Measles in Patients with Oncological Disease

Kharit,

Fridman,

Ruleva

2024

Epidemiology and Vaccinal Prevention

View full text Add to dashboard Cite

Relevance. Growing distrust of vaccines around the world, a decrease in vaccination rates have led to an increase in the incidence of measles and a rise in the vulnerability of people with immunodeficiency status. The aim. To study the efficacy and safety of measles vaccination in children with oncohematological diseases. Materials & methods. The study involved 107 children: 74 of them with a history of acute lymphoblastic leukemia and 33 with solid tumors. All children had a history of receiving standardized polychemotherapy. In all the subjects, the vaccination history was studied, the titers of specific antibodies to measles were determined. Children with non-protective levels of antibodies (53 children) were subsequently vaccinated against measles. Results and discussions. Of the 107 children examined, before cancer, 99 (92.5%) were vaccinated against measles, of which 68 (68.7%) patients were only vaccinated, and 31 (31.3%) had vaccination and revaccination. Protective titers of antibodies against measles were preserved in 51 people (51.5%), and 48 (48.5%) were seronegative. When assessing immunogenicity on days 14, 45 after the introduction of the vaccine, it turned out that by day 14, 27 out of 53 children (50.9%) developed measles antibodies, and by day 45, 33 out of 53 children (62.3%), the rest of the children did not developed a protective level of antibodies, including 3 of 6 revaccinated. Conclusion. Thus, children with malignant diseases, regardless of the number of previous vaccinations and the duration of the end of therapy, become unprotected or have low titers of antibodies to measles in 83.8%, and immunization after treatment is effective in 62.3% of cases.

show abstract

Vaccination of Patients With Oncology Diseases Against Measles and Mumps

Cited by 2 publications

References 10 publications

Characteristics of Anti-Measles Immunity in Lung Transplant Candidates

Characteristics of Anti-Measles Immunity in Lung Transplant Candidates

Vaccination against Measles in Patients with Oncological Disease

Contact Info

Product

Resources

About